肿瘤疫苗的研究进展

• 作 者: 孔丽清
• 机 构: 河北省秦皇岛市第二医院,
• 出 处: 山西医药杂志(下半月刊)
• 发表日期: 2013年02期
• 关键词: 肿瘤疫苗 肿瘤免疫反应 复发和转移 单克隆抗体 肿瘤患者 实际应用 细胞型 临床试验 抗原疫苗 治疗型 树突状 载体 预防 术后 苗距 距离

肿瘤疫苗作为预防肿瘤患者术后复发和转移的有力手段,近年来已得到广泛的研究和应用[1]。目前,已有多种疫苗进入临床试验阶段。但是由于肿瘤免疫反应的复杂性,肿瘤疫苗距成为治疗型疫苗并真正走向临床实际应用尚有距离。目前的肿瘤疫苗主要有以细胞为载体的肿瘤疫苗、肿瘤抗原疫苗、单克隆抗体(mAb)肿瘤疫苗、树突状细胞型疫苗等。

Tumor vaccine as a powerful tool to prevent recurrence and metastasis of patients with cancer has been widely studied and applied in recent years [1]. Currently, a variety of vaccines have entered the clinical trial phase. However, due to the complexity of the tumor immune response, tumor vaccines are far away from becoming therapeutic vaccines and actually moving toward clinical application. The current tumor vaccines mainly include cell-based tumor vaccines, tumor antigen vaccines, monoclonal antibody (mAb) tumor vaccines and dendritic cell vaccines.